Israel’s Biotech Firm Sells Eye Treatment to Pfizer
World biggest drug maker buys genetic eye treatment for blindness from Israeli biotech firm
Pfizer Inc., the world's biggest drug maker, said on Wednesday (09.28.06) it had acquired a genetic eye treatment from Israeli biotech company Quark Biotech Inc. (QBI) in a multi-million dollar deal.
Daniel Zurr, president and CEO at QBI, would not disclose exact financial details regarding the agreement, which is subject to approval by the US Federal Trade Commission, but told Reuters the deal was in the "hundreds of millions of dollars".
Under the agreement Pfizer acquires an exclusive worldwide license to Quark's human gene RTP-801, thought responsible for most cases of blindness in the developed world, and to molecules that modify its expression or function.
Zurr said he was very pleased with the agreement with Pfizer and hoped it would increase foreign interest in the biotech market in Israel.
Ssource: Reuters
Filed under Eye Treatment
You may also like to read
- Law Firm Files Individual & Class Action Suit Against Bausch & Lomb as a Result of Potentially Blinding Fungal Infection
- Early Stage Stem Cell-based Ophthalmology R&D Company Gets Funding from Pfizer
- Pfizer Antibiotic Zithromax for Eye Infection May Bring Re-Infections
- Bausch & Lomb Facing US. Federal Lawsuit Over ReNu Contact Lens Solution
- Hope for Age Related Macular Degeneration with Lucentis
- Lasik Vision Institute Settles Lawsuit over Pricing
- Alternative To LASIK For Vision Correction
- 3 Million Dolalr LASIK Malpractice Verdict Against 2005 Cataract and Refractive Surgeon of the Year, Dr. Eric D. Donnefeld
- Free Eye Treatment for 6 Million Latin Americans and Caribbeans
- One-Year-Old Boy Need Assistance for Urgent Overseas Eye Treatment
